MLYS: Lorundrostat targets a 20M-patient U.S. market, with an NDA decision target of Dec. 22, 2026

What happened

Lorundrostat is positioned to treat uncontrolled or resistant high blood pressure and related chronic kidney disease (CKD) and obstructive sleep apnea (OSA). Trials reported blood-pressure and UACR benefits; UACR is a measure used to assess kidney health. Its accepted U.S. drug application has a decision target of Dec. 22, 2026, for a stated 20M-patient addressable market.

Confirmed

Global impact / market context

If approved, lorundrostat could give Mineralys a route to revenue from patients whose hypertension remains uncontrolled or resistant, including people with related CKD or OSA. The size of the stated patient population indicates potential reach, but commercial value depends on the decision and eventual uptake.

Analyst inference

The application has been accepted, but the article gives only a target date for a decision, not an approval or launch. Reported trial benefits provide a clinical rationale; they do not establish how many patients will use the drug or whether it will generate meaningful sales.

Analyst inference

What to watch

1. Watch for the decision by the Dec. 22, 2026 target date; approval would be a necessary step before lorundrostat could be marketed for this use. Confirmed
2. Look for further trial or regulatory details on blood pressure and UACR benefits, because the summary reports benefits but gives no effect sizes or study results. Analyst inference
3. If the drug is approved, patient uptake among people with uncontrolled or resistant hypertension will help determine whether the stated 20M-patient market translates into revenue. Analyst inference

Evidence

• Original source link unavailable